Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations
- 30 May 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 15 (6), 579-602
- https://doi.org/10.1517/13543784.15.6.579
Abstract
New triazole antifungals (voriconazole, posaconazole, ravuconazole and albaconazole) have been developed to meet the increasing need for new antifungals, and address the rising incidence of invasive fungal infections and the emergence of fungal resistance. This report describes the spectrum of activity of the newer-generation triazoles based on data from in vitro, animal and clinical studies. The authors discuss the use of these agents in combination with other antifungals, the extent of cross-resistance, their toxicity profile and pharmacokinetic properties. A total of two agents are currently available: voriconazole (which is becoming a primary treatment for the management of invasive aspergillosis) and posaconazole (which demonstrates a broad antifungal spectrum). A further two agents, albaconazole and ravuconazole, are undergoing early clinical evaluation and their future is uncertain. For all newer triazoles, concerns about emerging drug-resistant fungi and the incidence and management of breakthrough infections will dictate their role in antifungal prophylaxis and treatment.Keywords
This publication has 97 references indexed in Scilit:
- Sinus zygomycosis in a patient receiving voriconazole prophylaxisBritish Journal of Haematology, 2005
- In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and CambodiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agentsDiagnostic Microbiology and Infectious Disease, 2004
- Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell TransplantsNew England Journal of Medicine, 2004
- Voriconazole Salvage Treatment of Invasive CandidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Echinocandin antifungal drugsThe Lancet, 2003
- In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus sppDiagnostic Microbiology and Infectious Disease, 2003
- Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazoleClinical and Experimental Dermatology, 2001
- Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2000
- In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.Journal of Antimicrobial Chemotherapy, 1999